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Supplementary Methods 
Tryptic digestion 
Protein samples were reduced with 3 mM DTT in 50 mM ammonium bicarbonate (AmBic) and 
heated at 60 °C for 10 minutes. Free cysteine residues were subsequently alkylated with 14 mM 
iodoacetamide (dark, at room temperature, 30 minutes). Excess iodoacetamide was quenched 
upon addition of DTT to a final concentration of 7 mM. Proteins were digested overnight with tryp-
sin (2% w/w) at 37 °C.  
Titanium dioxide enrichment  
Titansphere Phos-TiO2 spin tips (GLSciences) were conditioned with solution A (2 % TFA, 80 % 
MeCN) by centrifugation at 3000 x g for 2 minutes and then equilibrated with solution B (25 % lac-
tic acid, 1.5 % TFA, 60 % MeCN), centrifuging as before. Peptides were diluted with solution B, 
loaded on to the tip and centrifuged at 1000 x g for 10 minutes. Unbound material (flow through) 
was re-loaded on to the tip and centrifuged again to increase phosphopeptide recovery. Spin col-
umns were washed using solution B followed by solution A. Phosphopeptides were eluted from 
the tips with 5% ammonium hydroxide (1000 x g, 5 minutes) followed by 5% (v/v) pyrrolidine solu-
tion (1000 x g, 5 minutes). Samples were dried to completion by vacuum centrifugation and re-
constituted with water: acetonitrile (97:3) containing 0.1% (v/v) TFA.  
LC-MS/MS and data analysis 
Tryptic peptides were analysed by LC-MS/MS before and after titanium dioxide-based phospho-
peptide enrichment. nLC-ESI-MS/MS analysis was performed using either an Orbitrap Fusion 
Tribrid mass spectrometer (ThermoScientific) attached to a Ultimate 3000 nano system (Dionex), 
or an AmaZon ETD ion trap (Bruker Daltonics) arranged in-line with nanoAcquity n-UHPLC sys-
tem (Waters). The tandem mass spectra for all identified phosphopeptides were interrogated 
manually.  
Orbitrap Fusion LC-MS/MS method Peptides were loaded onto the trapping column (Thermo 
Scientific, PepMap100, C18, 300 μm X 5 mm), using partial loop injection, for seven minutes at a 
flow rate of 9 μL/min with 2% (v/v) MeCN 0.1% (v/v) TFA and then resolved on an analytical col-
umn (Easy-Spray C18 75 µm x 500 mm 2 µm bead diameter column) using a gradient of 96.2% A 
(0.1% FA) 3.8% B (80%  MeCN 19.9% H2O 0.1%  FA) to 50% B over 30 minutes at a flow rate of 
300 nL min-1.. A full scan mass spectrum was acquired over m/z 400-1500 in the Orbitrap (60K 
resolution at m/z 200) and data-dependent MS/MS analysis performed using a top speed ap-
proach (cycle time of 3 s), using either HCD and/or ETcaD fragmentation modes, with product 
ions being detected in the ion trap (rapid mode).  
AmaZon ETD LC-MS/MS method Peptides were loaded onto a trapping column (Waters Sym-
metry C18, 5 µm packing material, 180 µm x 20 mm) for three minutes with a flow rate of 5 µL/min 
with solvent A (0.1% (v/v) FA), and then resolved on a Waters nanoACQUITY C18 analytical col-
umn (1.8 µm packing material, 75 µm x 150 mm) using a gradient of 97% A, 3% B (0.1% (v/v) 
formic acid in MeCN) to 40% B over 60 min at 300 nL/min. A full scan mass spectrum was ac-
quired over m/z 150-2000 and the three most abundant ions selected for isolation and fragmenta-
tion by CID and ETD. Dynamic exclusion was set to 1 minute. CID was performed with helium as 
the target gas, with the MS/MS fragmentation amplitude set at 1.20 V, and ramped from 30 to 
300% of the set value.   
 ThermoScientific .raw files were converted to .mgf files in Proteome Discoverer. HCD and ETcaD 
spectra were separated according to ETD reaction time (<39 ms selects HCD spectra) generating 
two separate .mgf files which could be assigned as HCD or ETcaD spectra; they were then 
merged using an in-house Perl script. Bruker data files were converted to .mgf files using Com-
passXport software (Bruker Daltonic). 
The resulting .mgf files were searched using MASCOT (version 2.1) against the E. coli IPI data-
base (downloaded 24th March 2015) with the sequence of His-tagged PKA-Cα included. Parame-
ters were set as follows: MS1 tolerance of 10 ppm (Fusions) or 0.6 Da (AmaZon); MS/MS mass 
tolerance of 0.6 Da; carbamidomethylation of cysteine was set as a fixed modification; phosphory-
lation of serine and threonine, oxidation of methionine and deamidation of asparagine and gluta-
mine were set as variable modifications.  
 
  
Supplementary Table 1. Sites of auto-phosphorylation identified on recombinant wild-type PKA 
(catalytic domain), PKA-Cα WT, by reverse-phase chromatography of tryptic peptides and tan-
dem mass spectrometry using either collision-mediated dissociation (CID/HCD) or electron-
transfer dissociation (ETD). Mass, observed charge states, fragmentation mode, maximum 
MASCOT ion score and maximum delta score are indicated for each phosphopep-
tide/phosphosite. Mascot delta score gives an indication of degree of confidence in phosphosite 
localisation within a given peptide sequence. Where phosphosite localisation is potentially ambig-
uous, the alternate site with respect to the residues within the peptide sequence (alt. site) is also 
indicated. Novel sites of phosphorylation are marked with an asterisk. Tag indicates a phospho-
sites identified in the purification tag. 
Peptide Site  Mass Charge States 
HCD/CID/ 
ETD 
Max. Ion Score  
(Delta: alt. site) 
MHHHHHHpSpSGLVPR  Tag 1827.73 2+, 3+, 4+ HCD 66 
QHMDpSPDLGTDDDDK Tag 1767.64 2+, 3+ HCD 36 (24: Thr10) 
KGpSEQESVK  Ser10 1070.47 2+ HCD/ETD 42 (30: Ser7) 
KGpSEQESVKEFLAK  Ser10 1658.77 3+ ETD 44 (32: Ser7) 
WETPpSQNTAQLDQFDR  Ser34 2014.84 2+, 3+ CID 52 (21: Thr3) 
KWETPpSQNTAQLDQFDR  Ser34 2142.94 2+, 3+ HCD 91 (20:Thr4) 
WETPSQNpTAQLDQFDR  *Thr37 2014.83 3+ CID 40 (2: Ser5) 
KWETPSQNpTAQLDQFDR  *Thr37 2142.94 3+ HCD 77 (0: Ser6) 
IKpTLGTGSFGR  Thr48 1215.60 2+ HCD 26 (13: Thr6) 
IKpTLGTGpSFGR  Thr48, Ser53 1295.57 2+ HCD 27 (7: Thr3, Thr6) 
TLGpTGSFGR  Thr51 974.42 2+ HCD 30 (1:Thr1, Ser6) 
IKTLGpTGSFGR  Thr51 1215.60 3+ HCD 53 (12: Thr3) 
TLGTGpSFGR  Ser53 974.42 2+ CID 43 (23: Thr4) 
HKEpSGNHYAMK  *Ser65 1380.56 2+, 3+ HCD/ETD 45 
IGRFpSEPHAR  Ser139 1248.58 2+, 3+ HCD/ETD 33 
TWpTLCGTPEYLAPEIILSK  Thr197 2271.09 2+, 3+ HCD 79 (2: Thr1) 
FPpSHFSSDLK  Ser259 1243.53 2+, 3+ HCD/ETD 54 (24: Ser6) 
VpSINEK  Ser338 768.34 2+ HCD/ETD 27 
 
 
Supplementary Table 2. Sites of auto-phosphorylation identified on recombinant PKA R133A, by 
reverse-phase chromatography of tryptic peptides and tandem mass spectrometry using either 
collision-induced dissociation (CID) or electron-transfer dissociation (ETD). Mass, observed 
charge states, fragmentation mode, maximum MASCOT ion score and maximum delta score are 
indicated for each phosphopeptide/phosphosite. Mascot delta score gives an indication of degree 
of confidence in phosphosite localisation within a given peptide sequence. Where phosphosite 
localisation is potentially ambiguous, the alternate site with respect to the residues within the pep-
tide sequence (alt. site) is also indicated. Novel sites of phosphorylation are marked with an aster-
isk.  
Peptide Site Mass Charge States CID/ETD 
Max. Ion Score 
(Delta: alt. site) 
MHHHHHHpSpSGLVPR Tag 1827.57 4+ CID 34 
QHMDpSPDLGTDDDDKMGNAAAAK Tag 2481.89 3+ CID 62 (46: Thr10) 
GpSGMKETAAAK Tag 1129.45 2+, 3+ ETD 80 (64) 
GpSGMKETAAAKFER Tag 1561.58 2+, 3+ ETD 63 (23) 
GpSEQESVKEFLAK  Ser10 1530.51 3+ ETD 32 (19: Ser6) 
KGpSEQESVK  Ser10 1070.33 2+ CID 48 (39: Ser7) 
KGpSEQESVKEFLAK  Ser10 1658.64 2+, 3+ ETD 57 (28: Ser7) 
MGNAAAAKKGpSEQESVK  Ser10 1784.67 2+, 3+ ETD 66 (41: Ser15) 
WEpTPSQNTAQLDQFDR  *Thr32 2014.75 3+ CID 28 (2: Ser5) 
WETPpSQNTAQLDQFDR  Ser34 2014.79 2+, 3+ CID 72 (26: Thr3) 
KWETPpSQNTAQLDQFDR  Ser34 2142.96 3+ CID 38 (6: Thr9) 
KWETPSQNpTAQLDQFDR  *Thr37 2142.76 3+ CID 42 (0: Ser6) 
IKpTLGTGpSFGR  Thr48, Ser53 1295.53 2+ CID 42 (0: Thr3, Thr6) 
IKTLGpTGSFGR  Thr51 1215.54 2+ CID 59 (2: Ser8) 
TLGTGpSFGR  Ser53 974.37 2+ CID 60 (31: Thr4) 
IKTLGTGpSFGR  Ser53 1215.47 2+, 3+ ETD/CID 53 (19: Thr6) 
HKEpSGNHYAMK  *Ser65 1380.60 3+ ETD 46 
VMLVKHKEpSGNHYAMK  *Ser65 1950.94 2+, 3+ ETD 54 
IGRFpSEPHAR  Ser139 1248.48 3+ ETD 29 
TWpTLCGTPEYLAPEIILSK  Thr197 2271.10 2+, 3+ CID 72 (12: Thr1) 
GRTWpTLCGTPEYLAPEIILSK  Thr197 2484.19 3+ CID 32 (0: Thr3) 
GPGDTSNFDDYEEEEIRVpSINEK  Ser338 2721.97 3+ CID 36 (30: Ser6) 
FKGPGDTSNFDDYEEEEIRVpSINEK  Ser338 2997.21 3+, 4+ ETD/CID 54  
   
   
Supplementary Table 3. Sites of auto-phosphorylation identified on Mn2+-lambda protein phospha-
tase treated recombinant PKA WT, by reverse-phase chromatography of tryptic peptides and tandem 
mass spectrometry using either collision-induced dissociation (CID) or electron-transfer dissociation 
(ETD). Mass, observed charge states, fragmentation mode, maximum MASCOT ion score and maxi-
mum delta score are indicated for each phosphopeptide/phosphosite. Mascot delta score gives an in-
dication of degree of confidence in phosphosite localisation within a given peptide sequence. Where 
phosphosite localisation is potentially ambiguous, the alternate site with respect to the residues within 
the peptide sequence (alt. site) is also indicated. Novel sites of phosphorylation are marked with an 
asterisk.  
Peptide Site Mass Charge States CID/ETD
Max. Ion Score 
(Delta: alt. site) 
KpSEQESVKEFLAK Ser10 1658.79 3+ ETD 58 (45: S7) 
TLGTGpSFGR Ser53 974.42 2+ HCD 33 (12: T4) 
FpSEPHAR Ser139 922.37 2+ HCD 24  
TWpTLCGTPEYLAPEIILSK Thr197 2271.09 3+ HCD 52 (1: T1) 
FPpSHFSSDLK Ser259 1243.53 3+ ETD 40 (22: S6) 
GPGDTSNFDDYEEEEIRVpSINEK Ser338 2722.13 3+ HCD 45 (25: S6) 
 
 
Supplementary Figure 1. Collision dissociation product ion tandem mass spectra of triply charged ion 
(top) identifying phosphorylation of Thr32 and (bottom) identifying phosphorylation at Thr37. Matched 
product ions are indicated. 
 
 
 
Supplementary Figure 2. TWCCSN2→He for each of the four charges states observed following ESI-IM-
MS of wild-type PKA-Cα under non-denaturing conditions. 
 
 
Supplementary Figure 3. Collision-induced unfolding profiles of PKA wild type (black line), λPP treat-
ed wild type (red dashed line), R133A (blued dotted line) and K72H (green dashed/dotted line). 
TWCCSN2→He is shown for each step of increased trap collision energy (V). 
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Supplementary Figure 4. Activity of purified WT (blue) or R133A (red) PKAc in the presence of in-
creasing concentrations of PKI as assessed by kinetic assay using fluorescent Kemptide as substrate. 
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Supplementary Figure 5. Size exclusion chromatography (SEC) investigation of holoenzyme complex 
formation between catalytic (PKA-Cα) and regulatory (RIIα) PKA subunits. PKA-Cα WT and RIIα were 
analysed by SEC separately (A) or following pre-incubation at 4°C for 2 h in the absence (B) or pres-
ence of PKI (C).  Eluted fractions (0.5 ml) were collected and protein detected following SDS-PAGE 
and Coomassie staining. At the concentrations used, PKI could not be detected by Coomassie and is 
therefore not shown. PKA-Cα K72H was also analysed (D) and formation of a RIIα: K72H PKA-Cα 
complex assessed (E). Evidence for co-elution of catalytic and regulatory subunit, which is indicative of 
holoenzyme complex formation, was only detected for WT PKA-Cα, and was blocked upon inclusion of 
PKI. Holoenzyme formation was completely abolished for K72H (E). 
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Supplementary Figure 6. Native ESI-MS demonstrating partial dissociation of non-covalently bound 
small molecule ligands to WT PKAc arising from elevated collision energy applied in the transfer region 
of the Synapt G2-Si. 
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Supplementary Figure 7. Native ESI mass spectra acquired with increasing (bottom to top) transfer 
collision energy for PKA WT (blue circle) in the presence of staurosporine (yellow star) and PKI (red 
triangle). Collision energy applied (V) is shown on the left. 
 
	
